Circulating Biomarkers in Pulmonary Arterial Hypertension: An Update

Pulmonary arterial hypertension (PAH) is a rare subtype of group 1 pulmonary hypertension (PH) diseases, characterized by high pulmonary artery pressure leading to right ventricular dysfunction and potential life-threatening consequences. PAH involves complex mechanisms: vasoconstriction, vascular remodeling, endothelial dysfunction, inflammation, oxidative stress, fibrosis, RV remodeling, cellular hypoxia, metabolic imbalance, and thrombosis. These mechanisms are mediated by several pathways, involving molecules like nitric oxide and prostacyclin. PAH diagnosis requires clinical evaluation and right heart catheterization, confirming a value of mPAP ≥ 20 mmHg at rest and often elevated pulmonary vascular resistance (PVR). Even if an early and accurate diagnosis is crucial, PAH still lacks effective biomarkers to assist in its diagnosis and prognosis. Biomarkers could contribute to arousing clinical suspicion and serve for prognosis prediction, risk stratification, and dynamic monitoring in patients with PAH. The aim of the present review is to report the main novelties on new possible biomarkers for the diagnosis, prognosis, and treatment monitoring of PAH.

Endothelial Function in Pulmonary Arterial Hypertension: From Bench to Bedside

Pulmonary arterial hypertension is a complex pathology whose etiology is still not completely well clarified. The pathogenesis of pulmonary arterial hypertension involves different molecular mechanisms, with endothelial dysfunction playing a central role in disease progression. Both individual genetic predispositions and environmental factors seem to contribute to its onset. To further understand the complex relationship between endothelial and pulmonary hypertension and try to contribute to the development of future therapies, we report a comprehensive and updated review on endothelial function in pulmonary arterial hypertension.

988 UNCLEAR SUDDEN DEATH IN THE YOUNG: DIFFERENT DISTRIBUTION AMONG THE ITALIAN REGIONS

Introduction

Sudden death (SD) in the young due to cardiovascular diseases remains a focus of the public health system. It occurs unexpectedly in apparently healthy people. In addition, several of the diseases that cause sudden death in the young can be diagnosed and treated prior to the first lethal event; on the other hands, a post mortem approach, by the means of clinical autopsy and molecular autopsy, may clarify the underling disease to better develop futher prevention by a familial approach. The attention on this issue has greatly sensitized doctors and public opinion.

Aim

The aim of the manuscript was to evaluate the frequency of sudden deaths in Italy in the decade 2008-2017.

Methods and Data sources

The searches were carried out by consulting the database of the National Institute of Statistics (ISTAT). We counted in the ISTAT database all the deceased under the age of 40 due to unclear causes in the decade 2008-2017.

Results

We counted 7159 young patients with DS, unevenly distributed throughout the Italian territory. In detail, 10% (1373) were in the North-West, 14% (988) in the North-East, 13% (934) in the Center, 44% (3178) in the South and 10% (686) in the islands.

The analysis showed how the unclear SD in Italy have decreased over time. Southern Italy had the highest number (357) of SD at the start of the observation which slightly dropped to 272 in 2017. Despite this significant reduction, the South remains the place where the largest number of unclear SD are counted. Most likely, the initial studies conducted in the Veneto region sensitized doctors to SD in young people and athletes, leading a wider screening through cardiological examination and electrocardiogram for prevention; furthermore a widespread recurrence to clinical autopsy, to reach a clear diagnosis, allows the awareness that other cases could occur in the same family. Grief coping approach and cultural competency may explain the regional difference. The new methods available to genetics, such as next generation sequency (NGS), have allowed an increase in diagnoses even in the deceased and have identified possible pathogenic genes in family members.

Conclusions

Sudden death in young people represents an important challenge, considering the number of events that occur in our country and the different distribution in the Italian regions.

Medical community need to better address this issue, by implementing both prevention and post-mortem analysis, to reduce the sudden death burden, especially in southern region.

Thiene G. Sudden cardiac death in the young: a genetic destiny? Clin Med (Lond). 2018 Apr 1;18(Suppl 2):s17-s23. Markwerth P, Bajanowski T, Tzimas I, Dettmeyer R. Sudden cardiac death-update. Int J Legal Med. 2021 Mar;135(2):483-495.Webster G, Carberry T, Berger S. Screening for prevention of sudden death in the young: what is new? Curr Opin Cardiol. 2020 Jan;35(1):80-86.